GeoVax to Present Corporate Update at Noble Capital Markets Emerging Growth Conference

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company focused on developing human vaccines and cancer immunotherapies, announced that Chairman and CEO David Dodd will present at NobleCon21, the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference. The presentation is scheduled for December 3, 2025, at 3:00 pm ET at the Florida Atlantic University Executive Education Complex in Boca Raton, Florida.

The corporate update presentation provides investors with critical insights into GeoVax's clinical development pipeline and strategic direction. This appearance at a prominent financial conference signals the company's ongoing efforts to engage with the investment community and showcase its progress in developing novel medical solutions. The timing is significant as GeoVax advances multiple clinical programs that address substantial unmet medical needs in both infectious diseases and oncology.

GeoVax's lead clinical program, GEO-CM04S1, represents a next-generation COVID-19 vaccine currently undergoing three Phase 2 clinical trials. These trials are evaluating the vaccine as a primary option for immunocompromised patients, including those with hematologic cancers, where current authorized COVID-19 vaccines have shown limitations. Additional studies are examining its effectiveness as a booster for patients with chronic lymphocytic leukemia and as a more robust, durable booster for healthy individuals previously vaccinated with mRNA vaccines. The development of improved vaccines for vulnerable populations could significantly impact public health outcomes and reduce healthcare burdens.

In oncology, GeoVax is advancing Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. This therapeutic approach represents an innovative strategy in cancer treatment, potentially offering new options for patients with limited treatment alternatives. The company's progress in this area demonstrates the expanding potential of immunotherapy in addressing challenging cancer types.

GeoVax is also developing a vaccine targeting Mpox and smallpox, with recent regulatory guidance suggesting the potential to advance directly to Phase 3 clinical evaluation, bypassing earlier phase trials. This accelerated pathway could expedite the availability of additional protection against these serious infectious diseases. Investors and interested parties can access detailed information about the company's clinical trials and development programs through the corporate website at https://www.geovax.com.

A high-definition video webcast of the presentation will be available the day following the live event through Noble Capital Markets' conference website at https://www.nobleconference.com and on Channelchek at https://www.channelchek.com. The webcast will remain archived for 90 days following the conference, providing extended access to the corporate update. Senior GeoVax management will also conduct one-on-one meetings with registered attendees, offering deeper engagement opportunities for serious investors.

The company's participation in this emerging growth conference comes at a pivotal time for the biotechnology sector, where innovative approaches to vaccine development and cancer treatment are increasingly important. GeoVax's diverse portfolio and strong intellectual property position, with worldwide rights for its technologies and products, position the company as a significant player in the evolving landscape of medical biotechnology. The outcomes of these clinical developments could have far-reaching implications for patient care, public health infrastructure, and investment opportunities in the healthcare sector.